Provides a definitive overview of the complex ecosystem facilitating Alzheimer's Disease drug research and development. Demonstrates a drug's journey from in the lab, clinical trial testing, regulatory review, and marketing by pharmaceutical companies. Details the use of artificial intelligence, clinical trial management, and financing models.
Nearly 44 million people have Alzheimer's or related dementia worldwide, according to the Alzheimer's Disease International organization. That number is expected to double every 20 years. Unlike other books on the market, Alzheimer's Disease: Understanding Biomarkers, Big Data, and Therapy covers recent advancements in cognitive, clinical, neural, and therapeutic aspects of Alzheimer's and other forms of dementia.First, readers are introduced to cognitive and clinical studies, focusing on the different types of memory impairment, past and future thinking. This includes the prevalence of depression, its relationship to other symptoms, and the quality of life for those with Alzheimer's disease. In addition, the book discusses recent studies on memory dysfunction in advanced-stage Alzheimer's disease, in comparison to early-stage, including a chapter on the underlying factors in the transition from mild cognitive impairment to Alzheimer's diagnosis. Following this section, the book presents recent studies on the role of different cortical and subcortical structures in the development of various symptoms in Alzheimer's disease, as well as different neural biomarkers underlying the development and treatment of the disease. In the last section of the book, therapeutic aspects of Alzheimer's disease, focusing on behavioral and pharmacological treatments of sleep disorders, memory problems, and depression, are reviewed. The book aids readers in understanding the advances in research and care, making it a prime tool for all clinicians, psychologists, researchers, neurologists, and caregivers of dementia patients. - Reviews recent developments of cognitive and clinical studies - Covers factors underlying the transition from mild cognitive impairment to Alzheimer's disease - Discusses different neural biomarkers underlying the development and treatment of Alzheimer's disease - Provides a comparison of the effectiveness of various types of treatments
Drug Design and Discovery in Alzheimer's Disease includes expert reviews of recent developments in Alzheimer's disease (AD) and neurodegenerative disease research. Originally published by Bentham as Frontiers in Drug Design and Discovery, Volume 6and now distributed by Elsevier, this compilation of the sixteen articles, written by leading global researchers, focuses on key developments in the understanding of the disease at molecular levels, identification and validation of molecular targets, as well as innovative approaches towards drug discovery, development, and delivery. Beginning with an overview of AD pharmacotherapy and existing blockbuster drugs, the reviews cover the potential of both natural and synthetic small molecules; the role of cholinesterases in the on-set and progression of AD and their inhibition; the role of beta-site APP clearing enzyme-1 (BACE-1) in the production of ß-amyloid proteins, one of the key reasons of the progression of AD; and other targets identified for AD drug discovery. - Edited and written by leading experts in Alzheimer's disease (AD) and other neurodegenerative disease drug development - Describes existing drugs for AD and current molecular understanding of the condition - Reviews recent advances in the field, including coverage of cholinesterases, BACE-1, and other drug development targets
Neuroprotection in Alzheimer's Disease offers a translational point-of-view from both basic and clinical standpoints, putting it on the cusp for further clinical development with its emphasis on nerve cell protection, including the accumulation of knowledge from failed clinical trials and new advances in disease management. This book brings together the latest findings, both basic, and clinical, under the same cover, making it easy for the reader to obtain a complete overview of the state-of-the-field and beyond. Alzheimer's disease is the most common form of dementia, accounting for 60 to 80 percent of dementia cases. It is a progressive brain disease that slowly destroys memory, thinking skills, and eventually, even the ability to carry out the simplest tasks. It is characterized by death of synapses coupled to death nerve cells and brain degeneration which is manifested by loss of cognitive abilities. Understanding neuroprotection in Alzheimer's disease will pave the path to better disease management and novel therapeutics. - Comprehensive reference detailing neuroprotection in Alzheimer's Disease, with details on nerve cell protection and new advances in disease management - Combines the knowledge and points-of-view of both medical doctors and basic scientists, putting the subject at the forefront for further clinical development - Edited by one of the leading researchers in Alzheimer's Disease
Recent Advances in Alzheimer Disease Research is a book series focusing on contemporary research on Alzheimer’s disease epidemiology, pathophysiology, diagnosis and therapy. The series features reviews by experts in neuroscience and aims to provide current information in the field to both researchers and clinicians. Down syndrome is a chromosomal disorder affecting more than 5.8 million individuals worldwide. Down syndrome can be viewed as a complex multi-system disorder as it manifests into significant physical, psychological, and cognitive abnormalities in affected persons. With aging, most adults with Down syndrome develop the clinical and neuropathological hallmarks of Alzheimer's disease. Unfortunately, no extant treatments have proven beneficial for cognitive dysfunction for either Down syndrome or Alzheimer’s disease. An incomplete understanding of the common pathogenic mechanisms that link these two disorders has limited researchers’ progress to this end. Common Pathogenic Mechanisms between Down syndrome and Alzheimer's Disease: Steps toward Therapy is a novel attempt to fill this void, by summarizing the work of world-renowned scientists in the field of Alzheimer’s disease and Down syndrome, and thus providing an unprecedented opportunity to attract attention to Down syndrome as a tool for understanding the common molecular mechanisms that underlie Alzheimer’s disease and to develop new therapies for similar neurodegenerative disorders of the brain. The book covers the fundamental pathophysiology and molecular mechanisms behind the incidence of Alzheimer’s disease in Down syndrome affected individuals as well other key topics such as diagnosis and management, in vivo brain imaging studies, and progressive neurodegeneration of the monoaminergic system. The book concludes with a review of recent clinical trials of drugs designed to mitigate cognitive dysfunction in aging adults with Down syndrome and establishes a scientific warrant for the increased testing of candidate pharmacotherapies. Common Pathogenic Mechanisms between Down syndrome and Alzheimer's Disease: Steps toward Therapy is a useful reference clinicians involved in treating Down syndrome patients as well as for neuroscience researchers seeking to understand the influence of a specific case of aneuploidy on Alzheimer’s disease incidence and its progression at the molecular level.
The 3rd World Congress on Genetics, Geriatrics, and Neurodegenerative Disease Research (GeNeDis 2018), focuses on recent advances in genetics, geriatrics, and neurodegeneration, ranging from basic science to clinical and pharmaceutical developments. It also provides an international forum for the latest scientific discoveries, medical practices, and care initiatives. Advanced information technologies are discussed, including the basic research, implementation of medico-social policies, and the European and global issues in the funding of long-term care for elderly people.
The Neurobiology of Aging and Alzheimer Disease in Down Syndrome provides a multidisciplinary approach to the understanding of aging and Alzheimer disease in Down syndrome that is synergistic and focused on efforts to understand the neurobiology as it pertains to interventions that will slow or prevent disease. The book provides detailed knowledge of key molecular aspects of aging and neurodegeneration in Down Syndrome by bringing together different models of the diseases and highlighting multiple techniques. Additionally, it includes case studies and coverage of neuroimaging, neuropathological and biomarker changes associated with these cohorts. This is a must-have resource for researchers who work with or study aging and Alzheimer disease either in the general population or in people with Down syndrome, for academic and general physicians who interact with sporadic dementia patients and need more information about Down syndrome, and for new investigators to the aging and Alzheimer/Down syndrome arena. - Discusses the complexities involved with aging and Alzheimer's disease in Down syndrome - Summarizes the neurobiology of aging that requires management in adults with DS and leads to healthier aging and better quality of life into old age - Serves as learning tool to orient researchers to the key challenges and offers insights to help establish critical areas of need for further research
Researchers have tried various effective treatments that prevent the progressive neurodegeneration of neurons within the brain. Parkinson’s disease (PD), Alzheimer’s disease (AD), and Multiple sclerosis (MS) are some of the most common neurodegenerative diseases (NDDs). Recent Advances in the Treatment of Neurodegenerative Disorders provides interesting updates on treatments of these neurological disorders. Ten chapters have been contributed by experts in pharmacology and give a unique perspective to reader on special topics in this area, including the treatment of neurodegenerative treatment of neurodegenerative disease through ayurveda and phytochemicals, the therapeutic role of vitamins in Parkinson’s disease, mushrooms in NDD treatment, MS treatment, ALS treatment and the use of nanoparticles and nano formulations in NDD treatment. This is an informative reference for pharmacologists, medicinal chemists and healthcare professionals (general practitioners and neurologists) seeking updates in the treatment of some common neurodegenerative disorders.
As the largest generation in U.S. history - the population born in the two decades immediately following World War II - enters the age of risk for cognitive impairment, growing numbers of people will experience dementia (including Alzheimer's disease and related dementias). By one estimate, nearly 14 million people in the United States will be living with dementia by 2060. Like other hardships, the experience of living with dementia can bring unexpected moments of intimacy, growth, and compassion, but these diseases also affect people's capacity to work and carry out other activities and alter their relationships with loved ones, friends, and coworkers. Those who live with and care for individuals experiencing these diseases face challenges that include physical and emotional stress, difficult changes and losses in their relationships with life partners, loss of income, and interrupted connections to other activities and friends. From a societal perspective, these diseases place substantial demands on communities and on the institutions and government entities that support people living with dementia and their families, including the health care system, the providers of direct care, and others. Nevertheless, research in the social and behavioral sciences points to possibilities for preventing or slowing the development of dementia and for substantially reducing its social and economic impacts. At the request of the National Institute on Aging of the U.S. Department of Health and Human Services, Reducing the Impact of Dementia in America assesses the contributions of research in the social and behavioral sciences and identifies a research agenda for the coming decade. This report offers a blueprint for the next decade of behavioral and social science research to reduce the negative impact of dementia for America's diverse population. Reducing the Impact of Dementia in America calls for research that addresses the causes and solutions for disparities in both developing dementia and receiving adequate treatment and support. It calls for research that sets goals meaningful not just for scientists but for people living with dementia and those who support them as well. By 2030, an estimated 8.5 million Americans will have Alzheimer's disease and many more will have other forms of dementia. Through identifying priorities social and behavioral science research and recommending ways in which they can be pursued in a coordinated fashion, Reducing the Impact of Dementia in America will help produce research that improves the lives of all those affected by dementia.
Animal Experimentation: Working Towards a Paradigm Change critically appraises current animal use in science and discusses ways in which we can contribute to a paradigm change towards human-biology based approaches.
